HomeREGULATORY
REGULATORY

Azithromycin under PMDA Risk Review for Acute Generalized Exanthematous Pustulosis
(Jul.19.2017)

The Pharmaceuticals and Medical Devices Agency (PMDA) is reviewing the risks of acute generalized exanthematous pustulosis for the macrolide antibiotic azithromycin - a move that is likely to result in label changes affecting a large number of companies ...
(LOG IN FOR FULL STORY)

News Calendar